缺血性卒中疑似大血管闭塞AI检测的NTAP计费应用相关患者与机构因素
结果显示AI使用率逐年上升,2022年达峰值21%,使用与CT成像、综合卒中中心及大床位机构相关,校正后2022年OR为6.0、卒中带OR为2.0、综合卒中中心OR为1.5,患者人口学及卒中严重程度未见差异。
要点
- NTAP计费AI用于LVO检测在需溶栓的AIS住院病例中逐年增加,2022年达21%。
- AI使用更多见于有CT成像、综合卒中中心及≥1000床位机构。
- 校正后AI使用 odds 最高在2022年、卒中带及综合卒中中心,患者因素无差异。
核心结论
- NTAP计费AI用于AIS溶栓病例的LVO检测在2020至2022年增加,主要由机构因素驱动,而非患者因素或卒中严重程度。
研究设计与样本
- AI使用通过NTAP ICD-10代码4A03X5D识别,卒中严重程度和就医可及性分别用验证量表和区域剥夺指数评估。
- 采用卡方检验评估关联,并用随机效应逻辑回归模型在病例层面评估NTAP计费AI使用的 odds,以考虑机构层面聚类。
诊断标准与关键数值
- NTAP计费AI使用率在需溶栓治疗的AIS住院病例中逐年增加,2022年峰值21%。
- 校正逻辑回归中,2022年使用 odds 最高(OR 6.0,95% CI 2.7-13.3)。
- 卒中带受益人使用 odds 升高(OR 2.0,95% CI 1.3-3.0),综合卒中中心使用 odds 升高(OR 1.5,95% CI 1.1-2.0)。
临床应用与阅片要点
- 了解NTAP计费AI的使用趋势有助于评估机构LVO检测流程的采纳情况。
- AI使用存在机构与地理差异,报告时需注意综合卒中中心、大床位机构及卒中带的较高使用概率。
- 患者人口学与卒中严重程度未见使用差异,提示AI采纳可能不直接反映病例组合。
局限性
- 研究为回顾性设计,仅基于Medicare 5%样本,可能存在选择偏倚。
- AI使用仅通过NTAP计费代码识别,可能遗漏未计费或编码错误的使用。
- 分析限于需溶栓治疗的AIS住院病例,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Medicare's New Technology Add-On Payment (NTAP) incentivizes the adoption of innovative technologies. We examined factors associated with the use of NTAP-billed artificial intelligence (AI) software for detecting large vessel occlusion (LVO) in acute ischemic stroke (AIS) patients requiring thrombolytic treatment.
METHODS: Using nationally representative Medicare 5% Research Identifiable Files, inpatient AIS episodes billed under diagnosis-related groups (DRGs) 61-63 from October 2020 to December 2023 (NTAP period) were analyzed. AI use was identified via NTAP ICD-10 code 4A03X5D. Stroke severity and access to care were assessed using validated scales and the Area Deprivation Index. Associations between NTAP-billed AI use and patient, clinical, and facility characteristics were evaluated using chi-square tests. Odds of NTAP-billed AI use at the AIS inpatient visit level were evaluated with logistic regression models employing random effects to account for facility-level clustering.
RESULTS: Among 2,116 AIS episodes across 1,076 facilities, NTAP-billed AI use among inpatient AIS episodes requiring thrombolytic treatment increased annually, peaking at 21% in 2022. NTAP-billed AI use was most common in episodes with CT imaging, at comprehensive stroke centers, and in facilities with ≥1000 beds. No disparities in NTAP-billed AI use were observed across patient demographics or stroke severity measures. In adjusted logistic regression models, odds of NTAP-billed AI use were highest in 2022 (OR 6.0, 95% CI 2.7-13.3), among beneficiaries in the Stroke Belt (OR 2.0, 95% CI 1.3-3.0), and at comprehensive stroke centers (OR 1.5, 95% CI 1.1-2.0).
CONCLUSION: NTAP-billed AI adoption for LVO detection in AIS episodes requiring thrombolytic treatment increased from 2020 to 2022 and appeared to be driven by institutional factors, suggesting facility characteristics, rather than patient factors and stroke severity, may influence NTAP-billed AI use, potentially contributing to geographic variability in stroke care.
引用
- Pelzl CE, Christensen EW, Drake AR, et al. Patient and Facility Factors Associated with Uptake of NTAP-Billed AI to Identify Suspected LVO in Ischemic Stroke. AJNR Am J Neuroradiol. 2026. PMID: 42342375. doi:10.3174/ajnr.A9494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。